Loading cancer entity…
Loading cancer entity…
Clinical trials
47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04544111 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | active not recruiting | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00001160 | Studies on Tumors of the Thyroid | recruiting | — | 2,500 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02152995 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03914300 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07545837 | Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | recruiting | N/A | 20 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06959641 | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 33 | Jochen LorchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06730321 | Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS) | recruiting | — | 200 | Shanghai 6th People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04948437 | Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer | active not recruiting | — | 103 | National Taiwan University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05463107 | Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer | active not recruiting | — | 50 | National Taiwan University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02143726 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer | active not recruiting | Phase 2 | 35 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06440850 | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | recruiting | Phase 2 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05668962 | Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials